Possible cardiotoxicity due to CA4P administration has been described in veterinary medicine as increased serum cTnI levels, transient systemic arterial hypertension, sinus bradycardia, sinus tachycardia, and ventricular arrhythmias [2,3]. Here, TNNI3 is linked to Sinus bradycardia.